Uptake and fate of surface modified silica nanoparticles in head and neck squamous cell carcinoma
- Emina Besic Gyenge†1Email author,
- Xenia Darphin†1,
- Amina Wirth2,
- Uwe Pieles2,
- Heinrich Walt3,
- Marius Bredell3 and
- Caroline Maake1
© Besic Gyenge et al; licensee BioMed Central Ltd. 2011
Received: 8 February 2011
Accepted: 11 August 2011
Published: 11 August 2011
Head and neck squamous cell carcinoma (HNSCC) is currently the eighth leading cause of cancer death worldwide. The often severe side effects, functional impairments and unfavorable cosmetic outcome of conventional therapies for HNSCC have prompted the quest for novel treatment strategies, including the evaluation of nanotechnology to improve e.g. drug delivery and cancer imaging. Although silica nanoparticles hold great promise for biomedical applications, they have not yet been investigated in the context of HNSCC. In the present in-vitro study we thus analyzed the cytotoxicity, uptake and intracellular fate of 200-300 nm core-shell silica nanoparticles encapsulating fluorescent dye tris(bipyridine)ruthenium(II) dichloride with hydroxyl-, aminopropyl- or PEGylated surface modifications (Ru@SiO2-OH, Ru@SiO2-NH2, Ru@SiO2-PEG) in the human HNSCC cell line UMB-SCC 745.
We found that at concentrations of 0.125 mg/ml, none of the nanoparticles used had a statistically significant effect on proliferation rates of UMB-SCC 745. Confocal and transmission electron microscopy showed an intracellular appearance of Ru@SiO2-OH and Ru@SiO2-NH2 within 30 min. They were internalized both as single nanoparticles (presumably via clathrin-coated pits) or in clusters and always localized to cytoplasmic membrane-bounded vesicles. Immunocytochemical co-localization studies indicated that only a fraction of these nanoparticles were transferred to early endosomes, while the majority accumulated in large organelles. Ru@SiO2-OH and Ru@SiO2-NH2 nanoparticles had never been observed to traffic to the lysosomal compartment and were rather propagated at cell division. Intracellular persistence of Ru@SiO2-OH and Ru@SiO2-NH2 was thus traceable over 5 cell passages, but did not result in apparent changes in cell morphology and vitality. In contrast to Ru@SiO2-OH and Ru@SiO2-NH2 uptake of Ru@SiO2-PEG was minimal even after 24 h.
Our study is the first to provide evidence that silica-based nanoparticles may serve as useful tools for the development of novel treatment options in HNSCC. Their long intracellular persistence could be of advantage for e.g. chronic therapeutic modalities. However, their complex endocytotic pathways require further investigations.
Head and neck squamous cell carcinoma (HNSCC) comprise a group of epithelial cancers that arise from e.g. the lips, the oral or nasal cavity, salivary glands, paranasal sinuses, pharynx or larynx . With a worldwide incidence of more than 600'000 new cases per year, HNSCC accounts for about 6% of all malignant diseases diagnosed (http://globocan.iarc.fr). If detected early, patients have cure rates of about 90%. However, 60% of patients present with advanced disease or loco-regional lymph node metastasis at the time of diagnosis and have a poor prognosis [2, 3].
Currently, treatment options for HNSCC patients include surgery, radiotherapy, chemotherapy or a combination of them [4, 5]. Due to the distinct localization of these tumors in regions with anatomic structures important to e.g. breathing, mastication, swallowing or phonation, invasive treatment regimes frequently leading to severe functional impairments - often accompanied by unfavorable cosmetic outcomes. This is true despite significant advancements made in the reconstructive abilities over past two decades. Moreover, radiation may have long-term effects on surrounding healthy structures such as parts of the brain, the spinal cord or salivary glands. However, while surgery or radiation therapy is local, chemotherapy is applied systemically and may thus result in severe adverse effects e.g. on blood cell production (anaemia, neutropenia, thrombopenia), the mucosa (mucositis), the auditory and vestibular system (ototoxicity) or the kidneys (nephrotoxicity). Despite this aggressive therapeutic regime, to date many patients with advanced disease cannot be cured and more then half of them die within five years [6–8]. HNSCC is thus currently the eighth leading cause of cancer death worldwide.
To overcome at least some of the challenges in the therapy of patients with advanced HNSCC, the application of nanoparticles has been evaluated with regard to their advantages for chemotherapeutic/medicinal, radiation and imaging strategies. Previous data indicates that cytotoxic drugs such as mitoxantron, cisplatin or paclitaxel as well as the photosensitizer 5,10,15,20-tetrakis(meso-hydroxyphenyl)porphyrin (mTHPP) encapsulated in superparamagnetic, liposome, albumin or methoxy poly(ethylene glycol)-poly(lactide-co-glycolide) (MPEG-PLGA) nanoparticles or polymeric micelles not only exhibit potent antitumor activity, but also displayed reduced side effects [9–13]. Furthermore, it has been reported that beta-emitting radionuclides attached to liposomes showed promising results when applied intratumorally and gold nanoparticles or nanoparticles with antisense oligonucleotides against the gene ataxia-telangiectasia-mutated (ATM) improved radiosensitivity in rodent head and neck cancer models [14–16]. In addition, superior imaging in head and neck cancers resulted from the use of superparamagnetic iron oxide nanoparticles, gold nanoparticles or gadolinium-labelled phosphorescent polymeric nanomicelles [17–22].
In the past years, silica-based nanoparticles have gained increasing interest for medical applications because of their biocompatibility, versatility and stability. Numerous in-vitro and in-vivo studies pointed towards their great potential for improving the efficacy of therapeutic agents in tumor cells by e.g. circumventing solubility and stability problems of certain drugs or enabling targeted delivery and controlled release strategies [23–25]. Moreover, silica nanomaterials have been proposed as promising medical tools for biosensing [26, 27] and imaging purposes .
However, to our knowledge, silica nanoparticles have not yet been investigated in the context of head and neck cancers. In this work, we assess the biological in-vitro behaviour of core-shell silica based nanoparticles on the HNSCC cell line UMB-SCC-745 with regard to their cytotoxicity, uptake, localization and intracellular fate.
2. Materials and methods
2.1. Synthesis of nanoparticles
Spherical core-shell silica nanoparticles encapsulating tris(bipyridine)ruthenium(II) dichloride [Ru(bpy)3]Cl2 as fluorescent dye were produced as described before . The method is based on an oil-in-water microemulsion of n-hexanol-TritonX100-cyclohexane, [Ru(bpy)3]Cl2, tetraethyl-orthosilicate (TEOS) and ammonia. The surface chemistry of mono-shell silica nanoparticles was modified by the addition of a mixture of TEOS and other organosilanes, such as 3-aminopropyltriethoxysilane (APTES) to generate aminopropyl and hydroxyl functionalities (Ru@SiO2-NH2 and Ru@SiO2-OH) at the nanoparticle surface. Similarly, PEGylated [Ru(bpy)3]Cl2-labeled dual-shell nanoparticles (Ru@SiO2-PEG) have been synthesized as previously described, using a mixture of TEOS and bis(silylated)polyethylene glycol (SPEGS) for growth of a PEGylated second shell . All the three types of nanoparticles have been fully characterized, as precedently described and have an average size ranging between 200 and 300 nm . The surface charge and the hydrophilic character of nanoparticles have been explored based on their electrophoretic mobility in nanopure water at neutral pH (Zetasizer Nano ZS, Malvern Instruments Ltd., UK).
2.2. Cell Culture
The head and neck squamous carcinoma cell line UMB-SCC-745 was kindly provided by Dr. Robert Mandić, Department of Otolaryngology, Philips University, Marburg, Germany. The UMB-SCC-745 was derived from the tonsil tumor of a 48-year-old man and has a distinct p53 single point mutation and loss of heterozygosity .
UMB-SCC-745 cells were cultured under standard conditions (37°C, 5% CO2, 95% air atmosphere) in growth medium, i.e. RPMI Medium (Invitrogen, Basel, Switzerland) supplemented with 10% fetal calf serum (FCS, Sigma-Aldrich, Buchs, Switzerland), 1% HEPES (Invitrogen), 1% MEM non essential amino acids (Invitrogen) and 1% penicillin and streptomycin (Invitrogen). The growth medium was changed every second day. The passage of the cells was performed by trypsination (trypsin 1×, Invitrogen) when reaching confluence, in general every 2-3 days.
Multicellular spheroids (3D cell culture)
For generation of multicellular spheroids, we applied a modified hanging drop method . Briefly, 96-well plates were coated with 60 μl of 1.5% agarose (Sigma-Aldrich) per well, in RPMI medium without FCS. Then 20 μl drops of UMB-SCC 745 cell solution (5000 cells/20 μl) were placed on the plate lid, the lid was positioned back to the plate and then kept overnight in the incubator (37°C, 5% CO2). The following day, 80 μl growth medium was added to the wells, the plates were shortly centrifuged and returned to the incubator. In order to avoid vibration, which has an influence on the formation of spheroids, the incubator should not be opened for the first 48 hours. After this initial time spheroids were stable in their form and reached the desired diameter of 150 μm two days later.
2.3. Proliferation assay
The cytotoxicity of nanoparticles was evaluated using a commercial cell proliferation assay (Cell Proliferation ELISA, BrdU, chemiluminescent, Roche, Basel, Switzerland). For this experiment the cells were cultured in black Greiner-96-well plates (2000 cells/well, Cellstar, Frickenhausen, Germany) with 100 μl growth medium at 37°C, 5% CO2 for 24 h. Subsequently the growth medium was replaced with fresh one containing Ru@SiO2-OH, Ru@SiO2-NH2 or Ru@SiO2-PEG nanoparticles at final concentrations ranging between 0.03 mg/ml - 0.5 mg/ml. Nanoparticles were ultrasonicated for 2 h before incubation to ensure their homogeneity. After nanoparticle incubation for 5 h, the cells were washed with phosphate buffered saline (PBS, Oxoid, Hampshire, United Kingdom) and incubated overnight with fresh growth medium containing BrdU-labeling agent. BrdU, which is incorporated only in viable cells during DNA synthesis, was detected with an ELISA immunoassay according to the recommendation of the manufacturer. The resulting signal was quantified by measuring the photons using a micro-plate luminometer with photomultiplier technology (BioTek, Luzern, Switzerland). The relative light units/second (rlu/s) directly correlates to the amount of DNA synthesis and hereby to the number of proliferating cells in the respective microcultures.
2.4. Exposure protocols of nanoparticles
For all experiments, nanoparticles were ultrasonicated for 2 h directly prior to use in cell culture.
For the uptake study the cells were seeded either on six-well plates (1'000'000 cells/well) for transmission electron microscopy (TEM) or on poly-L-lysine (PLL, 0.25 mg/ml, Sigma-Aldrich) -coated glass cover slips (50'000 cells, Hecht-Assistant, Sondheim, Germany) for confocal laser scanning microscopy (CLSM). The cells were then incubated with either Ru@SiO2-OH, Ru@SiO2-NH2 or Ru@SiO2-PEG nanoparticles (final concentrations 0.125 mg/ml) for different time periods (30 min, 1 h, 2 h, 5 h, 7 h, 12 h and 24 h) under cell culture conditions. After each time point cell aliquots were used for microscopic monitoring by CLSM and TEM.
Alternatively, multicellular spheroids were grown for 4 days in 96-well plates and also exposed to Ru@SiO2-OH and Ru@SiO2-NH2 nanoparticles for 5 h and 24 h, respectively, at final concentrations of 0.125 mg/ml under cell culture conditions. The nanoparticle distribution in spheroids was monitored only by CLSM.
For long-time experiments, cells were grown in six-well culture plates and incubated under cell culture conditions with Ru@SiO2-OH and Ru@SiO2-NH2 nanoparticles for 5 h (final concentrations 0.125 mg/ml). Following an extensive washing step with PBS, cells were directly passaged, re-seeded (500'000 cells/well) in cell culture plates and kept in culture until confluence (three days). The growth medium was exchanged every day. Passaging of the cells was continued until fifth passage. After each passage aliquots of the cells were used for evaluation by both CLSM and TEM.
For control experiments, cells or spheroids were cultured as above, but nanoparticle-containing medium was replaced by growth medium.
Protocols for CLSM(TCS-SP2 and TCS-SP5, Leica, Heerbrugg, Switzerland): After exposure to nanoparticles and washing steps, cells on cover slips were fixed for 15 min with PBS containing 1% paraformaldehyde (PFA, Sigma-Aldrich) and 0.33% saccharose (Sigma-Aldrich). Visualisation of nuclei were performed by incubation with 4'-6-diamidion-2-phenylindole (DAPI, 1 μg/ml, Roche) and mounted with GlycerGel mounting medium (Dako, Baar, Switzerland).
In experiments concerning multicellular spheroids, nuclei were stained with Hoechst staining dye (1 μg/ml, Sigma-Aldrich), which was added for the last hour of incubation. After incubation, the spheroids were collected, washed with PBS, fixed with PBS containing 1% PFA for 30 minutes, washed again with PBS and then monitored by confocal microscopy.
[Ru(byp)3]2+ complexes were excited with a 458 nm laser and detected in the range of 570 - 650 nm. Visualisation of nuclei (DAPI and Hoechst staining) was achieved with an excitation wavelength of 350 nm and a detection wavelength range of 450 - 500 nm.
Protocols for TEM(CM100, TEM, Philips, Guildford, UK): After nanoparticle incubation and washing steps cells were fixed with 2.5% glutaraldehyde (GA, Electron Microscopy Sciences, Hatfield, USA) and 0.8% PFA in 0.05 M dimethylarsenic acid sodium salt trihydrate (Na-Caco, Merck, Darmstadt, Germany) buffer at 1:9 ratio for 30 minutes. The samples were washed once with 0.05 M Na-Caco buffer and then fixed for 1 h with 2% osmium-tetra-oxide and 3% potassium hexacyano-ferrate (II) trihydrate (Sigma-Aldrich) at 1:1 ratio. After washing and centrifugation, cell pellets were transferred to 2.5% bacto agar (Agar Scinetific, Wetzlar, Germany), dehydrated in 70-100% ethanol and embedded in embedding medium (Glycidether 100 (Promega); dodecenylsuccinic-anhydride (Sigma-Aldrich); nadic methyl anhydride (Sigma-Aldrich) and N, N-dimethylbenzylamin purum (Sigma-Aldrich) as activator) for 24 h at 80°C. Sections (70 nm) were contrasted with uranyl acetate dihydrate (Sigma-Aldrich) and lead (II) citrate (Sigma-Aldrich) for 20 minutes each.
UMB-SCC-745 cells cultured on PLL coated cover slides were incubated for 5 hours with Ru@SiO2-PEG, Ru@SiO2-OH and Ru@SiO2-NH2 nanoparticles at final concentrations of 0.125 mg/ml. After incubation cells were fixed for 15 min with 1% PFA in PBS, permeabilized with 0.01% Triton-X 100 (Roche) for 1.5 min, blocked for 30 min at room temperature with 0.1% bovine serum albumine (BSA, Calbiochem, San Diego, USA) and washed with PBS. For labelling of early endosomes, rabbit anti-EEA1 antibody (1:300, stock concentration 1.3 mg/ml, Sigma-Aldrich) was used. Rabbit anti-Rab7 antibody (1:300, stock concentration 1.2 mg/ml, Sigma-Aldrich) was used to visualize late endosomes and for labelling of Golgi apparatus mouse anti-GM130 antibody (1:500, stock concentration 0.7 mg/ml, Abcam, Cambridge, UK) was used. Cells were incubated with primary antibodies for 2 h at room temperature or overnight at 4°C, washed and incubated with FITC-labelled donkey anti-rabbit or anti-mouse antibodies, respectively (both 1:500, Sigma-Aldrich), together with DAPI (1 μg/ml) for 1 h at room temperature. Lysosomes and mitochondria were visualized with Lysotracker Red and Mitotracker Orange respectively (working concentration for both 300 nM, Invitrogen). For examination by CLSM (Leica), [Ru(byp)3]2+ complexes and nuclei have been detected as described above, while for FITC excitation and detection wavelengths of 488 nm and 490-540 nm, respectively, have been used.
The large data corpus of recent years provides evidence that silica nanomaterials may have the potential to strongly improve cancer treatment and diagnosis. Silica nanomaterials feature the versatility necessary for tumor-specific modifications, stability in the often harsh environments of the body, ease of production and - more importantly - they are generally regarded as biocompatible. However, the latter clearly depends on many parameters such as particle size, surface modification, dose, exposure time or cell type used as model . With the aim to explore the suitability of silica nanoparticles for new concepts in the treatment of head and neck cancers we investigated as a first step the biological in-vitro behaviour of non-targeted 200-300 nm core-shell silica nanoparticles with three different surface modifications.
While both Ru@SiO2-OH and Ru@SiO2-NH2 nanoparticles displayed high uptake rates in our model, internalization of PEGylated silica nanoparticles was almost completely lacking under the same experimental conditions. Although we observed this effect in the related HNSCC line UMB-SCC 969 and in the human prostate carcinoma cell line PC-3 as well (unpublished data), other studies showed, in contrast to our results, that PEGylated silica nanoshells are at least able to attach to the outside of MCF-7 cells . However, PEG is known for its cell-repelling properties [35–37], but uptake efficiency may be increased by the addition of targeting ligands . Since grafting of nanoparticles with PEG has been reported to be advantageous for in-vivo applications - basically due to its increased half-live in circulation - and helpful for targeting, the generation of optimized Ru@SiO2-PEG may be worthwhile (work in preparation).
Although the plasma membrane is negatively charged, the different surface charges of (negatively charged) Ru@SiO2-OH and (positively charged) Ru@SiO2-NH2 nanoparticles had no considerable influence on cellular uptake kinetics in our model. This is in contrast to reports indicating that negatively charged nanomaterials are less effectively internalized . However, a large number of studies show that both cationic and anionic nanoparticles are capable of effectively passing the cell membrane .
Our data indicates that at nanoparticle concentrations of 0.125 mg/ml and below, no perturbances in cell cycle progression have been detected under our experimental conditions. An increase of cancer cell proliferation could be dangerous and hold dire consequences in clinical settings. This phenomenon has been reported in-vitro for melanoma cells and mesoporous silica nanoparticles , but has never been observed in our experiments. However, higher concentrations of Ru@SiO2-OH and Ru@SiO2-NH2 lead to reduced proliferation rates. While a slowdown in growth of tumor cells may be generally regarded as a positive effect in cancer treatment it should be emphasized that the underlying pathomechanisms in HNSCC are not clear yet. Previous in-vitro studies in other cancer cell lines have shown that cytotoxicity of silica nanoparticles, in relation to size and incubation time, may be due to oxidative stress with lipid peroxidation and membrane damage and/or an inflammatory response [41, 42]. A detailed analysis of the complex molecular pathways involved is therefore needed in order to estimate possible (wanted or unwanted) consequences for future therapeutic strategies. Because of the different experimental design (e.g. longer incubation times, different particle sizes, other cell lines) it is impossible to directly compare our cytotoxicity data with previous studies. However, head and neck cancer cells seem to display cell toxic effects at concentrations comparable to other cancer cells, e.g. cervical adenocarcinoma cells , osteosarcoma cells , lung adenocarcinoma cells [37, 41], and gastric and colon cancer cells . Despite this, nanoparticle concentrations have to be carefully adjusted: using the same nanoparticles and experimental conditions as here, PC-3 human prostate cancer cells displayed a proliferation stagnation of about 15 days after nanoparticle incubation, although metabolic rates have been found to be higher (Besic Gyenge et al., unpublished).
With regard to internalization processes of nanoparticles into cells, phagocytosis, pinocytosis and caveolin- or clathrin-driven endocytosis have all been proposed and seem to strongly depend on particle form, size and cell type used. With our experimental set-up, apparently two different routes of nanoparticle uptake occur in parallel: on the one hand, single particles enter HNSCC cells via membrane invaginations that ultrastructurally resemble clathrin-coated pits. The involvement of clathrin-coated pits in internalization mechanisms of silica nanoparticles had also been proposed in several previous in-vitro studies using specific inhibitors or confocal methods [45–48]. On the other hand, the observed bulk internalization of nanoparticles is likely related to non-clathrin mediated endocytosis. The latter process rather displays features of macropinocytosis, such as membrane ruffling. Notably, the different surface charges of our nanoparticles did not play an apparent role with regard to the observed uptake mechanisms. Detailed studies are now needed to further characterize the events taking place at the plasma membrane upon contact with our silica nanoparticles. However, the incidence of such different simultaneous endocytosis modes of silica nanoparticles is in accordance with a recent paper, where also discrete entry pathways have been observed for single and agglomerated amorphous silica nanoparticles . Furthermore, in mouse melanoma cells, internalization of latex particles of 200 nm (that corresponds approx. to the size of our particles) involved clathrin-coated pits, while latex particles of 500 nm (that corresponds approx. to our nanoparticle clusters) preferentially entered the cells via a clathrin-independent caveolin-associated pathway .
To characterize the intracellular fate of our silica nanoparticles within HNSCC, we next investigated their possible delivery into early and late endosomes and lysosomes. The localization of Ru@SiO2-OH and Ru@SiO2-NH2 in early endosomes indicates their processing to endocytotic pathways, however, a considerable number of particles obviously used a different route of trafficking, that did not involve EEA1-positive organelles. As long as these organelles have not been characterized, a possible role of nanoparticle's surface charge for endocytic processes cannot be defined. However, the acidic pH of early endosomes may explain the slightly higher frequency of (negatively charged) Ru@SiO2-OH in EEA1-containing vesicles.
While we cannot exclude that some Ru@SiO2-OH and Ru@SiO2-NH2 may have been shuttled back to the plasma membrane for segregation, the majority of nanoparticles remained intracellularly and accumulated in rather large vesicles 24 h after incubation. We propose that the latter is related to homotypic vesicle fusion. No transfer to Golgi apparatus-related pathways has been detected. More importantly, we found that nanoparticle-bearing vesicles did neither mature from early endosomes into (Rab7-positive) late endosomes nor locate to lysosomes. While both the known stability of silica-shell nanoparticles and possible cancer-related changes in endosomal sorting mechanisms may have prevented their targeting to degradation pathways, our data is in contrast to other studies showing that silica nanoparticles are in fact transferred to lysosomes [46, 47, 50]. Our results also differ from those of Rejman et al.  where a size-dependency of endocytotic pathways had been proposed. In this study, at least smaller latex particles (200 nm) passaged to late endosomes/lysosomes while only large particles (500 nm) did not . We therefore conclude that intracellular fate of nanoparticles not only depends on their size (or agglomeration status) but presumably also on cell line.
Although the exact nature of different endocytotic organelles in our model has to await further characterization, the strictly vesicle-associated occurrence of Ru@SiO2-OH and Ru@SiO2-NH2 in HNSCC may have contributed to their biocompatibility. In human melanoma cells it had been reported that an escape of silica nanoparticles to the cytoplasm resulted in changes of the cytoskeleton as well as of adhesion and migration properties . Whether the vesicular enclosure of our nanoparticles is a useful feature in the case of intracellular drug delivery strategies in HNSCC remains to be proven.
In addition to their relatively large diameter [52, 53], the absence of free Ru@SiO2-OH and Ru@SiO2-NH2 within the cytoplasm of HNSCC may have been the reason that nanoparticles never passed the nuclear membrane. Even though localizations of silica nanoparticles within the nucleus had been observed before , our data is in accordance with results from previous studies [53, 55, 56]. Recently, it had been shown that labeling with fluorophores may affect uptake kinetics and intracellular pathways of certain probes . However, due to encapsulation of the dye in our study, it is unlikely that [Ru(bpy)3]Cl2 may have influenced routes of nanoparticles within cells. Until now, very little is known about the intracellular long-term fate of silica nanoparticles and possible consequences of their persistence in biological systems. In human lung epithelial cells, Stayton et. al. observed a slow but active transfer of silica nanoparticles from the cytoplasm to the exterior environment . They showed that during the first 24 h almost 50% of nanoparticles exited the cells. In contrast, our data implicates that both internalized Ru@SiO2-OH and Ru@SiO2-NH2 remain within the cell and are apparently distributed between daughter cells at cell division. During the course of several passages, initially high nanoparticle amounts in individual cells become "diluted", but ultrastructurally are still found in vesicles. The reason for the observed differences in long-time persistence of Ru@SiO2-OH and Ru@SiO2-NH2 are not clear yet, but may also be related to as yet uncharacterised charge-dependent effects of nanoparticles on endolysosomal pathways. However, in addition of not featuring acute cell toxic effects, the presence of our silica nanoparticles over 15 days caused no visible changes in viability, proliferation or morphology in HNSCC. Of note, over the time course studied, ultrastructure of nanoparticles appears to remain unchanged. However, it cannot be excluded that discrete processes of nanoparticle degradation occurred. Recently, it had been reported that, depending on functionalization, integrity of silica nanoparticles may be impaired step-wise over time in simulated body fluid with regard to e.g. surface area, pore width or pore volume [59, 60].
Although the high uptake efficiency of Ru@SiO2-OH and Ru@SiO2-NH2 in our in-vitro mono-layer model was promising, optimized conditions are needed in case of solid HNSCC tumors where conditions of poorer vascularisation may exist. Our results in HNSCC spheroids, an established minitumor model, show that penetration depth of Ru@SiO2-OH and Ru@SiO2-NH2 does not reach beyond the first (outer) cell layer - independent of nanoparticle surface charge. This observation provides further evidence that our nanoparticles are not actively exocytosed. Stayton et. al. showed in-vitro that nanoparticles which were exocytosed in growth medium were taken up by other cells if not removed from growth medium . Given that nanoparticles are not transported transcellularly and apparently are incapable of passing the intercellular junction complexes, new delivery strategies have to be developed for multicellular poorly vascularized cancers.
In summary, our study is the first to provide evidence that core-shell silica nanoparticles may be useful tools for the development of novel therapeutic strategies with cancers of the head and neck region. However, before an encapsulation of pharmaceutical compounds or a functionalization with targeting and imaging moieties may be considered, a better understanding of how these nanoparticles interact with HNSCC cells on contact and after internalization is needed. Starting from our first steps towards clarification of endocytic pathways, further microscopic, immunocytochemical and molecular biological studies will elucidate nanoparticle sorting as well as their further intracellular fate, including possible degradation processes, or nanoparticle-mediated molecular cell responses.
We are thankful to Urs Ziegler and his team, especially Therese Bruggmann and Gery Barmettler for their help with confocal and transmission electron microscopy. We are also thankful to Tu-My Diep and Martin Steuble for their help in immunocytochemistry and fruitful scientific discussions.
- Tobias JS: Cancer of the head and neck. Bmj. 1994, 308: 961-966.View ArticleGoogle Scholar
- Amir Z, Kwan SY, Landes D, Feber T, Williams SA: Diagnostic delays in head and neck cancers. Eur J Cancer Care (Engl). 1999, 8: 198-203. 10.1046/j.1365-2354.1999.00165.x.View ArticleGoogle Scholar
- Hunter KD, Parkinson EK, Harrison PR: Profiling early head and neck cancer. Nat Rev Cancer. 2005, 5: 127-135. 10.1038/nrc1549.View ArticleGoogle Scholar
- Marur S, Forastiere AA: Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc. 2008, 83: 489-501. 10.4065/83.4.489.View ArticleGoogle Scholar
- Vermorken JB, Specenier P: Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol. 21 (Suppl 7): vii252-vii261.Google Scholar
- Berrino F, Gatta G: Variation in survival of patients with head and neck cancer in Europe by the site of origin of the tumours. Eur J Cancer. 1998, 34: 2154-2161. 10.1016/S0959-8049(98)00328-1.View ArticleGoogle Scholar
- Conway DI, McKinney PA, McMahon AD, Ahrens W, Schmeisser N, Benhamou S, Bouchardy C, Macfarlane GJ, Macfarlane TV, Lagiou P: Socioeconomic factors associated with risk of upper aerodigestive tract cancer in Europe. Eur J Cancer. 2009, 46: 588-598.View ArticleGoogle Scholar
- Conway DI, McMahon AD, Smith K, Black R, Robertson G, Devine J, McKinney PA: Components of socioeconomic risk associated with head and neck cancer: a population-based case-control study in Scotland. Br J Oral Maxillofac Surg. 48: 11-17.Google Scholar
- Alexiou C, Jurgons R, Schmid RJ, Bergemann C, Henke J, Erhardt W, Huenges E, Parak F: Magnetic drug targeting--biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment. J Drug Target. 2003, 11: 139-149.View ArticleGoogle Scholar
- Damascelli B, Patelli G, Ticha V, Di Tolla G, Frigerio LF, Garbagnati F, Lanocita R, Marchiano A, Spreafico C, Mattavelli F: Feasibility and efficacy of percutaneous transcatheter intraarterial chemotherapy with paclitaxel in albumin nanoparticles for advanced squamous-cell carcinoma of the oral cavity, oropharynx, and hypopharynx. J Vasc Interv Radiol. 2007, 18: 1395-1403. 10.1016/j.jvir.2007.06.009.View ArticleGoogle Scholar
- Boulikas T: Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin. Expert Opin Investig Drugs. 2009, 18: 1197-1218. 10.1517/13543780903114168.View ArticleGoogle Scholar
- Gao C, Pan J, Lu W, Zhang M, Zhou L, Tian J: In-vitro evaluation of paclitaxel-loaded MPEG-PLGA nanoparticles on laryngeal cancer cells. Anticancer Drugs. 2009, 20: 807-814. 10.1097/CAD.0b013e328330c811.View ArticleGoogle Scholar
- Cohen EM, Ding H, Kessinger CW, Khemtong C, Gao J, Sumer BD: Polymeric micelle nanoparticles for photodynamic treatment of head and neck cancer cells. Otolaryngol Head Neck Surg. 143: 109-115.Google Scholar
- Zou J, Qiao X, Ye H, Zhang Y, Xian J, Zhao H, Liu S: Inhibition of ataxia-telangiectasia mutated by antisense oligonucleotide nanoparticles induces radiosensitization of head and neck squamous-cell carcinoma in mice. Cancer Biother Radiopharm. 2009, 24: 339-346. 10.1089/cbr.2008.0557.View ArticleGoogle Scholar
- French JT, Goins B, Saenz M, Li S, Garcia-Rojas X, Phillips WT, Otto RA, Bao A: Interventional therapy of head and neck cancer with lipid nanoparticle-carried rhenium 186 radionuclide. J Vasc Interv Radiol. 21: 1271-1279.Google Scholar
- Hainfeld JF, Dilmanian FA, Zhong Z, Slatkin DN, Kalef-Ezra JA, Smilowitz HM: Gold nanoparticles enhance the radiation therapy of a murine squamous cell carcinoma. Phys Med Biol. 55: 3045-3059.Google Scholar
- Curvo-Semedo L, Diniz M, Migueis J, Juliao MJ, Martins P, Pinto A, Caseiro-Alves F: USPIO-enhanced magnetic resonance imaging for nodal staging in patients with head and neck cancer. J Magn Reson Imaging. 2006, 24: 123-131.View ArticleGoogle Scholar
- El-Sayed I, Huang X, Macheret F, Humstoe JO, Kramer R, El-Sayed M: Effect of plasmonic gold nanoparticles on benign and malignant cellular autofluorescence: a novel probe for fluorescence based detection of cancer. Technol Cancer Res Treat. 2007, 6: 403-412.View ArticleGoogle Scholar
- Mack MG, Rieger J, Baghi M, Bisdas S, Vogl TJ: Cervical lymph nodes. Eur J Radiol. 2008, 66: 493-500. 10.1016/j.ejrad.2008.01.019.View ArticleGoogle Scholar
- Popovtzer R, Agrawal A, Kotov NA, Popovtzer A, Balter J, Carey TE, Kopelman R: Targeted gold nanoparticles enable molecular CT imaging of cancer. Nano Lett. 2008, 8: 4593-4596. 10.1021/nl8029114.View ArticleGoogle Scholar
- Kumar R, Ohulchanskyy T, Turowski S, Thompson ME, Seshadri M, Prasad PN: Combined magnetic resonance and optical imaging of head and neck tumor xenografts using Gadolinium-labelled phosphorescent polymeric nanomicelles. Head Neck Oncol. 2010, 2: 35-10.1186/1758-3284-2-35.View ArticleGoogle Scholar
- Xie H, Wang ZJ, Bao A, Goins B, Phillips WT: In vivo PET imaging and biodistribution of radiolabeled gold nanoshells in rats with tumor xenografts. Int J Pharm. 2010, 395: 324-330. 10.1016/j.ijpharm.2010.06.005.View ArticleGoogle Scholar
- Slowing II, Vivero-Escoto JL, Wu CW, Lin VS: Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev. 2008, 60: 1278-1288. 10.1016/j.addr.2008.03.012.View ArticleGoogle Scholar
- Manzano M, Colilla M, Vallet-Regi M: Drug delivery from ordered mesoporous matrices. Expert Opin Drug Deliv. 2009, 6: 1383-1400. 10.1517/17425240903304024.View ArticleGoogle Scholar
- Vivero-Escoto JL, Slowing II, Trewyn BG, Lin VS: Mesoporous silica nanoparticles for intracellular controlled drug delivery. Small. 2010, 6: 1952-1967. 10.1002/smll.200901789.View ArticleGoogle Scholar
- Wang H, Yang R, Yang L, Tan W: Nucleic acid conjugated nanomaterials for enhanced molecular recognition. ACS Nano. 2009, 3: 2451-2460. 10.1021/nn9006303.View ArticleGoogle Scholar
- Zhong W: Nanomaterials in fluorescence-based biosensing. Anal Bioanal Chem. 2009, 394: 47-59. 10.1007/s00216-009-2643-x.View ArticleGoogle Scholar
- Lucignani G: Nanoparticles for concurrent multimodality imaging and therapy: the dawn of new theragnostic synergies. Eur J Nucl Med Mol Imaging. 2009, 36: 869-874. 10.1007/s00259-009-1104-2.View ArticleGoogle Scholar
- Legrand S: Controlling silica nanoparticles properties for biomedical applications through surface modification. 2008Google Scholar
- Fent K, Weisbrod CJ, Wirth-Heller A, Pieles U: Assessment of uptake and toxicity of fluorescent silica nanoparticles in zebrafish (Danio rerio) early life stages. Aquat Toxicol. 100: 218-228.Google Scholar
- Mandic R, Rodgarkia-Dara CJ, Zhu L, Folz BJ, Bette M, Weihe E, Neubauer A, Werner JA: Treatment of HNSCC cell lines with the EGFR-specific inhibitor cetuximab (Erbitux) results in paradox phosphorylation of tyrosine 1173 in the receptor. FEBS Lett. 2006, 580: 4793-4800. 10.1016/j.febslet.2006.07.064.View ArticleGoogle Scholar
- Kelm JM, Timmins NE, Brown CJ, Fussenegger M, Nielsen LK: Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types. Biotechnol Bioeng. 2003, 83: 173-180. 10.1002/bit.10655.View ArticleGoogle Scholar
- Napierska D, Thomassen LC, Lison D, Martens JA, Hoet PH: The nanosilica hazard: another variable entity. Part Fibre Toxicol. 2010, 7: 39-10.1186/1743-8977-7-39.View ArticleGoogle Scholar
- Huang Y, Swarup VP, Bishnoi SW: Rapid Raman imaging of stable, functionalized nanoshells in mammalian cell cultures. Nano Lett. 2009, 9: 2914-2920. 10.1021/nl901234x.View ArticleGoogle Scholar
- Tziampazis E, Kohn J, Moghe PV: PEG-variant biomaterials as selectively adhesive protein templates: model surfaces for controlled cell adhesion and migration. Biomaterials. 2000, 21: 511-520. 10.1016/S0142-9612(99)00212-4.View ArticleGoogle Scholar
- Blummel J, Perschmann N, Aydin D, Drinjakovic J, Surrey T, Lopez-Garcia M, Kessler H, Spatz JP: Protein repellent properties of covalently attached PEG coatings on nanostructured SiO(2)-based interfaces. Biomaterials. 2007, 28: 4739-4747. 10.1016/j.biomaterials.2007.07.038.View ArticleGoogle Scholar
- Akhtar MJ, Ahamed M, Kumar S, Siddiqui H, Patil G, Ashquin M, Ahmad I: Nanotoxicity of pure silica mediated through oxidant generation rather than glutathione depletion in human lung epithelial cells. Toxicology. 2010, 276: 95-102. 10.1016/j.tox.2010.07.010.View ArticleGoogle Scholar
- Bartlett DW, Davis ME: Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjug Chem. 2007, 18: 456-468. 10.1021/bc0603539.View ArticleGoogle Scholar
- Verma A, Stellacci F: Effect of surface properties on nanoparticle-cell interactions. Small. 6: 12-21.Google Scholar
- Huang X, Zhuang J, Teng X, Li L, Chen D, Yan X, Tang F: The promotion of human malignant melanoma growth by mesoporous silica nanoparticles through decreased reactive oxygen species. Biomaterials. 2010, 31: 6142-6153. 10.1016/j.biomaterials.2010.04.055.View ArticleGoogle Scholar
- Lin W, Huang YW, Zhou XD, Ma Y: In vitro toxicity of silica nanoparticles in human lung cancer cells. Toxicol Appl Pharmacol. 2006, 217: 252-259. 10.1016/j.taap.2006.10.004.View ArticleGoogle Scholar
- Choi SJ, Oh JM, Choy JH: Toxicological effects of inorganic nanoparticles on human lung cancer A549 cells. J Inorg Biochem. 2009, 103: 463-471. 10.1016/j.jinorgbio.2008.12.017.View ArticleGoogle Scholar
- Slowing I, Trewyn BG, Lin VS: Effect of surface functionalization of MCM-41-type mesoporous silica nanoparticles on the endocytosis by human cancer cells. J Am Chem Soc. 2006, 128: 14792-14793. 10.1021/ja0645943.View ArticleGoogle Scholar
- Chang JS, Chang KL, Hwang DF, Kong ZL: In vitro cytotoxicitiy of silica nanoparticles at high concentrations strongly depends on the metabolic activity type of the cell line. Environ Sci Technol. 2007, 41: 2064-2068. 10.1021/es062347t.View ArticleGoogle Scholar
- Chung TH, Wu SH, Yao M, Lu CW, Lin YS, Hung Y, Mou CY, Chen YC, Huang DM: The effect of surface charge on the uptake and biological function of mesoporous silica nanoparticles in 3T3-L1 cells and human mesenchymal stem cells. Biomaterials. 2007, 28: 2959-2966. 10.1016/j.biomaterials.2007.03.006.View ArticleGoogle Scholar
- Lu CW, Hung Y, Hsiao JK, Yao M, Chung TH, Lin YS, Wu SH, Hsu SC, Liu HM, Mou CY: Bifunctional magnetic silica nanoparticles for highly efficient human stem cell labeling. Nano Lett. 2007, 7: 149-154. 10.1021/nl0624263.View ArticleGoogle Scholar
- Hsiao JK, Tsai CP, Chung TH, Hung Y, Yao M, Liu HM, Mou CY, Yang CS, Chen YC, Huang DM: Mesoporous silica nanoparticles as a delivery system of gadolinium for effective human stem cell tracking. Small. 2008, 4: 1445-1452. 10.1002/smll.200701316.View ArticleGoogle Scholar
- Orr GA, Chrisler WB, Cassens KJ, Tan R, Tarasevich BJ, Markillie LM, Zangar RC, Thrall BD: Cellular recognition and trafficking of amorphous silica nanoparticles by macrophage scavenger receptor A. Nanotoxicology.Google Scholar
- Rejman J, Oberle V, Zuhorn IS, Hoekstra D: Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J. 2004, 377: 159-169. 10.1042/BJ20031253.View ArticleGoogle Scholar
- Hocine O, Gary-Bobo M, Brevet D, Maynadier M, Fontanel S, Raehm L, Richeter S, Loock B, Couleaud P, Frochot C: Silicalites and Mesoporous Silica Nanoparticles for photodynamic therapy. Int J Pharm. 402: 221-230.Google Scholar
- Huang X, Teng X, Chen D, Tang F, He J: The effect of the shape of mesoporous silica nanoparticles on cellular uptake and cell function. Biomaterials. 2009, 31: 438-448.View ArticleGoogle Scholar
- Chen M, von Mikecz A: Formation of nucleoplasmic protein aggregates impairs nuclear function in response to SiO2 nanoparticles. Exp Cell Res. 2005, 305: 51-62. 10.1016/j.yexcr.2004.12.021.View ArticleGoogle Scholar
- Nabeshi H, Yoshikawa T, Matsuyama K, Nakazato Y, Arimori A, Isobe M, Tochigi S, Kondoh S, Hirai T, Akase T: Size-dependent cytotoxic effects of amorphous silica nanoparticles on Langerhans cells. Pharmazie. 65: 199-201.Google Scholar
- Tao Z, Toms BB, Goodisman J, Asefa T: Mesoporosity and functional group dependent endocytosis and cytotoxicity of silica nanomaterials. Chem Res Toxicol. 2009, 22: 1869-1880. 10.1021/tx900276u.View ArticleGoogle Scholar
- Yu-Shen Lin, C-P T, Hsing-Yi Huang, Chieh-Ti Kuo, Yann Hung, Dong-Ming Huang, Yao-Chang Chen, Chung-Yuan Mou: Well-Ordered Mesoporous Silica Nanoparticles as Cell Markers. Chem Mater. 2005, 17 (18): 4570-4573. 10.1021/cm051014c.View ArticleGoogle Scholar
- Yu K, Grabinski C, Schrand A, Murdock R, Wang W, Gu B, Schlager J, Hussain S: Toxicity of amorphous silica nanoparticles in mouse keratinocytes. Journal of Nanoparticle Research. 2009, 11: 15-24. 10.1007/s11051-008-9417-9.View ArticleGoogle Scholar
- Puckett CA, Barton JK: Fluorescein redirects a ruthenium-octaarginine conjugate to the nucleus. J Am Chem Soc. 2009, 131: 8738-8739. 10.1021/ja9025165.View ArticleGoogle Scholar
- Stayton I, Winiarz J, Shannon K, Ma Y: Study of uptake and loss of silica nanoparticles in living human lung epithelial cells at single cell level. Anal Bioanal Chem. 2009, 394: 1595-1608. 10.1007/s00216-009-2839-0.View ArticleGoogle Scholar
- Cauda V: ASaTB: Bio-degradationnext term study of colloidal mesoporous previous termsilica nanoparticles:next term Effect of surface functionalization with organo-silanes and poly(ethylene glycol). Microporous and Mesoporous Materials. 2010, 132: 60-71. 10.1016/j.micromeso.2009.11.015.View ArticleGoogle Scholar
- He JS, Min Zhua, Yu Chen, Feng Chen: The three-stage in vitro degradation behavior of mesoporous silica in simulated body fluidnext term. Microporous and Mesoporous Materials. 2010, 131: 314-320. 10.1016/j.micromeso.2010.01.009.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.